Studies have shown that pancreatic cancer patients have a distinct tumor microenvironment, and those in stable or remission stages exhibit decreased levels of Treg cells, while IL-17A expression increases [10]. This evidence concerns the gene IL17A and familial pancreatic carcinoma.